Dr. Jarred T. Burkart, MD

Dr. Burkart practices at Columbus Oncology and Hematology Associates - HOPD in Columbus, Ohio.

Dr. Burkart's NPI, 1205102001, was assigned on March 26, 2012. Dr. Burkart graduated from Ohio State University College of Medicine in 2012. Dr. Burkart holds Ohio license 35.123346.

Dr. Burkart's primary practice is Columbus Oncology and Hematology Associates - HOPD, at 810 Jasonway Ave, Columbus, OH 43214.

Dr. Burkart's primary practice is Columbus Oncology and Hematology Associates - HOPD in Columbus, Ohio. Dr. Burkart is also affiliated with OhioHealth Riverside Methodist Hospital. The medical group on file is OhioHealth Physician Group. Dmand AI also links Dr. Burkart to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account. Dr. Burkart's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Burkart practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Burkart's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Burkart is licensed in Ohio.

CMS data shows 31,169 Medicare services from Dr. Burkart across 35 procedure codes in 2024, for 457 Medicare patients. Medicare paid $225,647 for them.

CMS counts 457 Medicare patients who saw Dr. Burkart in 2024. The largest group is 65 to 74, with 196 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Burkart's median patient age at 71, with 52% women.

In 2024, Dr. Burkart wrote 1,459 Medicare Part D claims for 193 patients. 77% of them were for generic drugs. CMS names the drug for 1,200 of them, across 37 drugs with 11 or more claims each, at $3,926,578 in total drug cost. In 2023, CMS named 970 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Burkart for performance year 2024, reported as part of a group. Dr. Burkart accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Burkart as offering telehealth.

Dmand AI links 10 papers to Dr. Burkart, published from 2012 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Immunotherapy, Drug-Related Side Effects and Adverse Reactions and Nivolumab. Dr. Burkart has published most often in Cancer Immunol Immunother. Dr. Burkart's most frequent co-authors are Gregory A. Otterson, MD, Kari L. Kendra, MD and Mingjia Li, MD.

CMS Open Payments shows 19 general payments to Dr. Burkart from 13 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 67% of the total. Daiichi Sankyo Inc. paid the most, $1,941.

Dr. Burkart graduated from Ohio State University College of Medicine in 2012.